Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Gurney

Showing results (11-20 of 135) with videos related to

Pageof 14
Sort By:
Asia-Pacific Journal of Clinical Oncology|May 11, 2017
Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access programPhillip Parente, Siobhan Ng, Francis Parnis, et al.
Journal of Nuclear Medicine Technology|November 9, 2021
<sup>18</sup>F-DCFPyL PET/CT in Metastatic Renal Cell CarcinomaGeoffrey M Currie, Marko Trifunovic, Jui Liu, et al.
The Oncologist|December 15, 2010
Inhibitors of mTORHeinz-Josef Klümpen, Jos H Beijnen, Howard Gurney, et al.
Cancer Medicine|August 24, 2017
Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survivalManish I Patel, Kieran Beattie, Albert Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Evidence for therapeutic drug monitoring of targeted anticancer therapiesBo Gao, Shang Yeap, Arthur Clements, et al.
Asia-Pacific Journal of Clinical Oncology|January 18, 2025
BRCA Mutation Testing in Men with Metastatic Castration-Resistant Prostate Cancer: Practical Guidance for Australian Clinical PracticeArun A Azad, Howard Gurney, Ainsley Campbell, et al.
Asia-Pacific Journal of Clinical Oncology|April 22, 2017
Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in AustraliaMegan Crumbaker, Alexander Guminski, Howard Gurney, et al.
Case Reports in Oncology|July 17, 2024
Polypoid Large Intestinal Involvement of Metastatic Castrate-Resistant Prostate Cancer: A Case ReportSathya Narayanan, Sapir Dvuchbabny, Arteen Arzivian, et al.
Sports Medicine - Open|February 15, 2020
The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance TrainingTeresa Lam, Vita Birzniece, Mark McLean, et al.
Asia-Pacific Journal of Clinical Oncology|September 20, 2023
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in AustraliaHoward Gurney, Timothy D Clay, Niara Oliveira, et al.
Pageof 14

Showing results (11-20 of 135) with videos related to

Sort By:
Pageof 14
Asia-Pacific Journal of Clinical Oncology|May 11, 2017
Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access programPhillip Parente, Siobhan Ng, Francis Parnis, et al.
Journal of Nuclear Medicine Technology|November 9, 2021
<sup>18</sup>F-DCFPyL PET/CT in Metastatic Renal Cell CarcinomaGeoffrey M Currie, Marko Trifunovic, Jui Liu, et al.
The Oncologist|December 15, 2010
Inhibitors of mTORHeinz-Josef Klümpen, Jos H Beijnen, Howard Gurney, et al.
Cancer Medicine|August 24, 2017
Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survivalManish I Patel, Kieran Beattie, Albert Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Evidence for therapeutic drug monitoring of targeted anticancer therapiesBo Gao, Shang Yeap, Arthur Clements, et al.
Asia-Pacific Journal of Clinical Oncology|January 18, 2025
BRCA Mutation Testing in Men with Metastatic Castration-Resistant Prostate Cancer: Practical Guidance for Australian Clinical PracticeArun A Azad, Howard Gurney, Ainsley Campbell, et al.
Asia-Pacific Journal of Clinical Oncology|April 22, 2017
Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in AustraliaMegan Crumbaker, Alexander Guminski, Howard Gurney, et al.
Case Reports in Oncology|July 17, 2024
Polypoid Large Intestinal Involvement of Metastatic Castrate-Resistant Prostate Cancer: A Case ReportSathya Narayanan, Sapir Dvuchbabny, Arteen Arzivian, et al.
Sports Medicine - Open|February 15, 2020
The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance TrainingTeresa Lam, Vita Birzniece, Mark McLean, et al.
Asia-Pacific Journal of Clinical Oncology|September 20, 2023
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in AustraliaHoward Gurney, Timothy D Clay, Niara Oliveira, et al.
Pageof 14